Paul E. Finke

2.4k citations

45 papers · 1.6k indexed · h-index 23

Co-authors: James B. Doherty Bonnie M. Ashe Malcolm MacCoss Sander G. Mills Alan L. Maycock Shrenik K. Shah Ki Taek Nam James R. Goldenring
Topics: Synthesis of β-Lactam Compounds (10 papers)Protease and Inhibitor Mechanisms (7 papers)Peptidase Inhibition and Analysis (5 papers)
Cited by: Virology Cancer Research Organic Chemistry
Journals: Nature Proceedings of the National Academy of Sciences Blood
Partner nations: United States United Kingdom South Korea

In The Last Decade

Paul E. Finke

45 papers receiving 1.5k citations

Peers

Countries citing papers authored by Paul E. Finke

Since Specialization

Citations

This map shows the geographic impact of Paul E. Finke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Finke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Finke more than expected).

Fields of papers citing papers by Paul E. Finke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Finke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Finke. The network helps show where Paul E. Finke may publish in the future.

Co-authorship network of co-authors of Paul E. Finke

This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Finke. A scholar is included among the top collaborators of Paul E. Finke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Finke. Paul E. Finke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression 2012 ·Gut ·Victoria G. Weis,Josane F. Sousa,Bonnie LaFleur,Ki Taek Nam,Jared A. Weis,Paul E. Finke,Nadia A. Ameen,James G. Fox,James R. Goldenring	4
2	Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells 2011 ·Gut ·Ki Taek Nam,Ryan O'Neal,Robert J. Coffey,Paul E. Finke,Nick Barker,James R. Goldenring	42
3	The fibrinogen cleavage product A -Val360, a specific marker of neutrophil elastase activity in vivo 2011 ·Thorax ·(unknown),Richard A. Mumford,(unknown),Paul E. Finke,Philip R. Davies,Qin Si,John L. Humes,Asger Dirksen,Eeva Piitulainen,Arsalan Ahmad,Robert A. Stockley	49
4	Mature Chief Cells Are Cryptic Progenitors for Metaplasia in the Stomach 2010 ·Gastroenterology ·Ki Taek Nam,(unknown),Josane F. Sousa,Victoria G. Weis,Ryan O'Neal,Paul E. Finke,Judith Romero–Gallo,Guanglu Shi,Jason C. Mills,Richard M. Peek,Stephen F. Konieczny,James R. Goldenring	223
5	Cyclopentane-based human NK1 antagonists. Part 2: Development of potent, orally active, water-soluble derivatives 2006 ·Bioorganic & Medicinal Chemistry Letters ·Laura C. Meurer,Paul E. Finke,Karen Owens,Nancy N. Tsou,Richard G. Ball,Sander G. Mills,Malcolm MacCoss,Sharon Sadowski,Margaret A. Cascieri,Kwei‐Lan Tsao,Gary G. Chicchi,Linda A. Egger,Silvi Luell,Joseph M. Metzger,D. Euan MacIntyre,N.M.J. Rupniak,Angela Williams,Richard Hargreaves	21
6	Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Christopher W. Plummer,Paul E. Finke,Sander G. Mills,Junying Wang,Xinchun Tong,George A. Doss,Tung M. Fong,Julie Lao,Marie‐Therese Schaeffer,Jing Chen,Chun-Pyn Shen,D. Sloan Stribling,Lauren P. Shearman,Alison M. Strack,Lex H.T. Van der Ploeg	46
7	Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes 2001 ·Bioorganic & Medicinal Chemistry Letters ·Paul E. Finke,Laura C. Meurer,Bryan Oates,Shrenik K. Shah,Jennifer L. Loebach,Sander G. Mills,Malcolm MacCoss,(unknown),Lorraine Malkowitz,Martin S. Springer,Sandra L. Gould,Julie A. DeMartino	31
8	Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure–Activity relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes 2001 ·Bioorganic & Medicinal Chemistry Letters ·Paul E. Finke,Bryan Oates,Sander G. Mills,Malcolm MacCoss,Lorraine Malkowitz,Martin S. Springer,Sandra L. Gould,Julie A. DeMartino,Anthony Carella,Gwen Carver,Karen Holmes,Renee Danzeisen,Daria J. Hazuda,Joseph Kessler,Janet Lineberger,Michael D. Miller,William A. Schleif,Emilio A. Emini	62
9	The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets 2000 ·Neuropharmacology ·F.D. Tattersall,Wayne Rycroft,M. Cumberbatch,G.S. Mason,Spencer J. Tye,David J. Williamson,(unknown),Sander G. Mills,Paul E. Finke,Malcolm MacCoss,Sharon Sadowski,E Ber,Margaret A. Cascieri,R.G. Hill,D. Euan MacIntyre,Richard Hargreaves	120
10	Formation of polymorphonuclear leukocyte elastase: α1 proteinase inhibitor complex and Aα(1–21) fibrinopeptide in human blood stimulated with the calcium ionophore A23187 1995 ·Biochemical Pharmacology ·Stephen G Pacholok,Philip R. Davies,Conrad P. Dorn,Paul E. Finke,William A. Hanlon,Richard A. Mumford,John L. Humes	10
11	An inhibitor of leukocyte elastase prevents immune complex-mediated hemorrhage in the rat lung. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·D. Fletcher,(unknown),(unknown),Robert J. Bonney,James B. Doherty,Paul E. Finke,Samir K. Shah,Philip R. Davies	7
12	Mechanism of inhibition of human leukocyte elastase by monocyclic .beta.-lactams 1993 ·Biochemistry ·Renee M. Chabin,(unknown),Philip A. Gale,Alan L. Maycock,(unknown),Conrad P. Dorn,Paul E. Finke,(unknown),Jeffrey J. Hale	19
13	Orally active .beta.-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution 1993 ·Journal of Medicinal Chemistry ·William K. Hagmann,(unknown),Shrenik K. Shah,Paul E. Finke,Conrad P. Dorn,(unknown),Bonnie M. Ashe,(unknown),Alan L. Maycock	22
14	Inhibition of human leukocyte elastase. 4. Selection of a substituted cephalosporin (L-658,758) as a topical aerosol 1992 ·Journal of Medicinal Chemistry ·Paul E. Finke,Shrenik K. Shah,Bonnie M. Ashe,Richard G. Ball,Thomas J. Blacklock,Robert J. Bonney,(unknown),Gilbert O. Chandler,Mark F. Cotton	45
15	Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives 1992 ·Biochemistry ·Wilson B. Knight,Alan L. Maycock,(unknown),Bonnie M. Ashe,Philip A. Gale,(unknown),Paul E. Finke,(unknown),Shrenik K. Shah,James B. Doherty	34
16	The Discovery and Biologic Properties of Cephalosporin‐Based Inhibitors of PMN Elastase 1991 ·Annals of the New York Academy of Sciences ·Philip R. Davies,Bonnie M. Ashe,Robert J. Bonney,Conrad P. Dorn,Paul E. Finke,D. Fletcher,William A. Hanlon,John L. Humes,Alan L. Maycock,Richard A. Mumford,Manuel A. Navia,Evan E. Opas,Stephen G Pacholok,(unknown),M.D. Zimmerman,James B. Doherty	24
17	PMN elastases: A comparison of the specificity of human isozymes and the enzyme from other species toward substrates and inhibitors 1991 ·Archives of Biochemistry and Biophysics ·(unknown),(unknown),Bonnie M. Ashe,James B. Doherty,Paul E. Finke,(unknown),Michael W. Lark,(unknown),Alan L. Maycock,Vernon L. Moore,Richard A. Mumford,Samir K. Shah,Lori A. Walakovits,Wilson B. Knight	31
18	Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins 1990 ·Journal of Medicinal Chemistry ·S. K. Shah,(unknown),Gilbert O. Chandler,Paul E. Finke,Bonnie M. Ashe,(unknown),Wilson B. Knight,Alan L. Maycock,James B. Doherty	43
19	Pharmacological profile of the substituted beta‐lactam L‐659,286: A member of a new class of human PMN elastase inhibitors 1989 ·Journal of Cellular Biochemistry ·Robert J. Bonney,Bonnie M. Ashe,Alan L. Maycock,Pam S. Dellea,(unknown),(unknown),D. Fletcher,Richard A. Mumford,Philip R. Davies,(unknown),T. Nolan,Laura Schaeffer,(unknown),Paul E. Finke,Samir K. Shah,C. Richard Dorn,James B. Doherty	27
20	Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase 1986 ·Nature ·James B. Doherty,Bonnie M. Ashe,Lawrence W. Argenbright,Peter L. Barker,Robert J. Bonney,Gilbert O. Chandler,Mary Ellen Dahlgren,Conrad P. Dorn,Paul E. Finke,Raymond A. Firestone,Daniel S. Fletcher,William K. Hagmann,Richard A. Mumford,Laura O’Grady,Alan L. Maycock,Judith M. Pisano,Shrenik K. Shah,Kevan R. Thompson,Morris Zimmerman	134

About Paul E. Finke

Paul E. Finke is a scholar working on Immunology and Allergy, Virology and Cancer Research, having authored 45 papers that have together received 1.6k indexed citations. Recurring topics across this work include Synthesis of β-Lactam Compounds (10 papers), Protease and Inhibitor Mechanisms (7 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Virology (85 citations), Cancer Research (248 citations) and Organic Chemistry (461 citations). Paul E. Finke has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include James B. Doherty, Bonnie M. Ashe, Malcolm MacCoss, Sander G. Mills, Alan L. Maycock, Shrenik K. Shah, Ki Taek Nam, James R. Goldenring, Ryan O'Neal and Richard A. Mumford. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact